A study in Uganda demonstrated that hydroxyurea conferred sustained neurocognitive benefits on children with Sickle Cell Anemia (SCA). The study was conducted on children 3-9 years in a 2.5 year, single-arm, open label trial. The results showed that hydroxyurea conferred multiple neurological benefits with improved cognition, attention, memory, concentration, analytic function, and planning. Neurological and cognitive improvements are caused by hydroxyurea's benefits which raises Hb and fetal Hb (HBF) which have a positive impact on improved general well-being and reduction in acute SCA complications, fewer blood transfusions, reduced risk of strokes, and sickle cell cerebrovascular injury. Effects of hydroxyurea on severity of cerebrovascular injury were measured by parameters such as neurocognitive functioning, incident of strokes, and abnormal transcranial Doppler (TCD) cerebral arterial flow velocity. Hydroxyurea in SCD works by enhancing oxygen delivery to the brain and vital organs, reducing vascular stress, and preventing or slowing brain injury. It stimulates the production of HbF and raises overall Hb levels, thus improving chronic hemolytic anemia and increases blood's oxygen-carrying capacity. It lowers risks of strokes and decreases the risk or progression of silent cerebral infarcts and overt strokes which are drivers of cognitive decline in SCD. It also suppreses cell-stress signaling and inflammation, decreases general severity of Vaso Occlusive Crises (VOC) in SCD which occur when sickled RBCs block capillaries cutting off oxygen supply and resulting in severe pain in chest, extremities, joints and bones, and reduces incidence of Acute Chest Syndrome, a complication of SCD and VOC. SCD is exacerbated by the higher burden of risk factors such as infections and poor socioeconomic status (SES). The results of the study underscore the importance of early initiation of hydroxyurea and increasing its access to all children with SCA in Sub Saharan Africa and other regions in the world with a high incidence of SCD.

"Wishing you my friends a good day ✨️ "Gaze of Silence" Paul Klee

In phase 3 of the DELLphi-305 Trial involving patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC), the median OS was 21.1 months when tarlatamab, a bispecific T-cell engager targeting delta-like ligand 3 (DLL3) and CD 3 was added to durvalumab, an anti-programed death ligand 1 agent, when administered as combination maintenance therapy vs 12.7 months with durvalumab alone with better progression-free survival. This significant improvement was achieved with the use of a combination of both immunotherapeutic agents after initial chemo-immunotherapy and after first remission when it is unclear. Adverse events (AEs) of grade 3 or higher occurred in 46.8% of patients receiving combination therapy and 40.6% in those who received durvalumab alone. Cytokine release syndrome (CRS) of grade 1 or 2 was seen in nearly half the patients receiving the combination therapy. ES-SCLC is a highly aggressive and rapidly progressing type of adenocarcinoma with poor prognosis. It occurs when cancer has spread beyond the lung where it started and metastasized to the contralateral lung, distant lymph nodes, and other organs like the brain, liver, and bones. It is driven by cumulative lifetime genetic mutations caused by smoking and environmental toxins that lead to the universal inactivation of key tumor-suppression genes specifically TP53 and RB 1. The new combination treatment under study holds the promise for longer overall survival for patients with ES-SCLC.

The importance of hepcidin assays in the diagnosis of iron disorders. Systemic iron homeostasis is predominantly controlled by hepcidin which is secreted by hepatocytes. Hepcidin is a peptide hormone, the central hormonal regulator of systemic iron homeostasis and a critical mediator and biomarker of iron disorders. It has a central role in controlling dietary iron absorption, iron recycling by macrophages, and iron storage through its interaction with the iron exporter ferroportin, a ferrous iron transporter that exports iron out of cells into the blood stream. Its synthesis is regulated by iron status, inflammation, and erythropoietic demand via hepatic bone morphogenetic protein-SMAD pathway and its modulators such as erythroferrone and IL-6-janus kinase-signal transducer and activator of transcription signaling. Hepcidin also acts as an acute-phase reactant during infections and inflammation. Genetic hepcidin deficiency causes hemochromatosis and predisposes to infections, whereas its excess causes iron-refractory-iron deficiency anemia (IRIDA). Hepcidin assays can be used to determine iron overload disorders, iron-loading anemia, transfusional iron overload, inherited IRIDA, inflammation, and erythroid activity. However, correct interpretation of hepcidin assays requires distinguishing hepcidin's role as a pathogenic driver vs a biomarker of disease. Currently, hepcidin assays are most helpful in complex or rare iron disorders where existing approaches are not sufficient for decision making strategies.

Despite advances in understanding Burkitt Lymphoma (BL), global survival gaps still exist. Novel insights into biomarkers have emerged with novel genomic analysis and new treaments such as targeted therapies with reduced toxicities have led to tailored therapies. However, survival disparities still persist especially in resource-limited settings where globally, most BL patients live, and among patients with relapsed/refractory Burkitt Lymphoma (R/R BL). BL is a rapidly-growing aggressive B-cell lymphoma classified into endemic, sporadic, or immunodeficiency-associated BL based on epidemiological features. Recent genomic and epidemiological studies distinguish Epstein-Barr virus (EBV)-positive and EBV-negative BL. In high-income countries (HICs), BL is 95% curable with early detection, intensive multi-agent chemotherapy, and antibody-based therapy. In contrast, survival in Sub-Saharan Africa (SSA), survival rarely exceeds 50%, reflecting diagnostic delays, high rates of treatment abandonment, and limited access to chemotherapy. Approximately 95% of EBV-positive BL predominate in pediatric SSA patients; in North Africa and Latin America, EBV is detectable in 40%-70% of cases. In Asia, reported EBV positivity varies between 20%-80%. Among individuals with HIV infection, 40%-70% of BL-positive patients are EBV positive. There is a strong correlation between P. falciparum, EBV infection, and BL. underlying the fact that some immune mechanisms at high risk to tolerate repeated malaria exposure and severe infections. Immune mechanisms in primary infection with EBV seem to confer protection against severe P. falciparum while increasing long-term BL risk among survivors, with some parasitic strains more oncogenic than others. The paradoxical interplay between infection with P. falciparum and BL suggests that BL develops in children who are otherwise resistant to severe malaria, with BL risk becomes significant only after a high number of repeated infections (>50) and continues to increase with additional exposure in malaria-resistant children which shows that P. falciparum is a critical driver of BL pathogenesis by modulating EBV. Althogh EBV persists silently in memory B-cells (latency 0), malaria-driven antigenic stimulation causes these cells to remember the germinal cells (GCs) thus reactivating EBV growth program (latency III) resulting in full protein expression, virion production, and shedding. Moreover, P. falciparum directly stimulates the proliferation of infected B-cells while at the same time, suppressing T-cell responses that normally control EBV. These processes significantly increase EBV viral load and shedding, explaining why children with BL have 5 to 13 times higher antibody titer against both pathogens than healthy persons. The pathogen interaction represents an evolutionary trade-off in which co-infection confers survival advantage to children and enhanced transmission of both pathogens. Early EBV infection in the first year of life provides a survival advantage against malaria-associated mortality in regions where malaria is endemic. EBV derived BH RF1/vIL-10 modulates host immune responses dampening excessive inflammation associated with severe malaria and reducing mortality, an effective immunomodulation that benefits both the host and P. falciparum pathogen. Germline susceptibilty to BL has been observed in rare inborn errors of immunity (IEI) including X-linked lympho-proliferative disease, X-MEN syndrome, ataxia telangiectasia, and Williams-Beuren syndromes. Germline variants that reduce malaria risk, such as sickle-cell trait and variants at ABO locus, are associated with decreased BL risk. The present analytical study underscores the importance of understanding the pathogenesis of BL, accurate diagnosis, the underlying genomics, and providing more accessible treatments in resource-limited regions in order to close the survival gaps in BL as BL is a highly curable disease with early detection.

Wishing you my friends a happy day ✨️ "The Soup" Pablo Picasso

The U.S. Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen), a first-in-class antisense oligonucleotide for the treatment of chronic hepatitis B (HBV) in adults without cirrhosis who have been taking HBV anti-viral therapy for at least 6 months and who have hepatitis B surface antigen (HBsAg) of 3,000 IU/mL or less. Bepirovirsen is administered as SC injections for up to 24 weeks together with existing hepatitis B therapy, which enables patients to stop the existing hepatitis B treatment. Studies have found that 24 weeks after stopping all HBV treatment, 19% of patients who received bepirovirsen, HBsAg was not detectable in their blood. Bepirovirsen targets the genetic instructions the virus uses to replicate itself and its proteins, thus helping to reduce the viral load and consequently, HBsAg. The FDA has also authorized the use of Elecsys HBsAg II quant II RxDx assay as a companion diagnostic device for the selection of chronic HBV infections and as a tool to monitor the course of the disease. Bepirovirsen however, comes with a boxed warning for serious adverse events (AEs) such as severe liver reactions and severe thrombocytopenia with life-threatening bleeding, worsening renal function, vasculitis, and serious risks if injections are not properly administered, underscoring the importance of regular blood testing and follow-ups before and during the treatment to monitor these serious risks. Bepirovirsen is a hopeful step for patients living with chronic HBV infection which may progress to liver cirrhosis and liver cancer.

The therapeutic relevance of macrolide antibiotics in the management of severe asthma. Asthma is an inflammtory disease of the airways characterized by variable airflow obstruction and inflammation. Asthma can be triggered by allergens, infections, irritants, some drugs like aspirin, cold air, or present as an exercise-induced bronchospasm. Asthma can be stratified into 2 main biological endotypes based on the underlying immune and inflammatory pathways: High-Type 2 (T2-High), characterized by elevated blood eosinophils (>300 cells/mcgL) driven by an overactive immune response involving Type 2 helper (TH2) cells and innate lymphoid cells (ILC2s) and cytokines (IL-4, IL-5, and IL-13) with elevated mast cells and elevated IgE-producing cells; and Low-Type 2 inflammation (T2-Low) with <300 cells/mcgL involving Th1,Th17 cells and IL-17, and IL-22. Patients with asthma require short-acting bronchodilators such as short-acting beta 2- agonists (SABAs), while patients with severe asthma may experience recurrent exacerbations despite maintenance therapy with medium-or high-dose inhaled corticosteroids and long acting beta-agonists (LABAs). These patients may also require additional therapies to achieve disease control such as anticholinergics and other drugs. Macrolides exhibit both anti-inflammatory and antimicrobial properties which may alleviate asthma symptoms. The results of the present study demonstrated that macrolides (azithromycin, clarithtomycin, and roxithromycin), improve asthma control, reduce severe exacerbations, and improve quality of life with little to no effect on serious adverse events (AEs) among patients with T2-High and T2-Low inflammation. Azithromycin remains the optimal macrolide due to its infrequent dosing, limited drug-drug interaction, and increased tolerability compared to clarithromycin. However, the widespread and prolonged use of macrolides have contributed to the emergence of macrolide-resistant pathogens including S. pneumoniae, M. pneumoniae, and multi-drug resistant N. gonorrhea which warrants close surveillance and reserving the use of macrolides to patients with severe asthma who have few other treatment options.

The great Artur Rubinstein plays Frederic Chopin's "Heroic" Polonaise No. 6 in A-flat Major, opus 53, "Heroic". Have a good day my friends ✨️ music.youtube.com/watch?v=_j…